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Abstract We analyzed prevention of mother-to-child
transmission (PMTCT) data from a retrospective cohort of
n = 1365 HIV? mothers who enrolled their HIV-exposed
infants in early infant diagnosis services in four Kenyan
government hospitals from 2010 to 2012. Less than 15 and
20 % of mother-infant pairs were provided with regimens
that met WHO Option A and B/B? guidelines, respectively. Annually, the gestational age at treatment initiation
decreased, while uptake of Option B/B? increased (all
p’s \ 0.001). Pediatric HIV infection was halved (8.6–
4.3 %), yet varied significantly by hospital. In multivariable analyses, HIV-exposed infants who received no
PMTCT (AOR 4.6 [2.49, 8.62], p \ 0.001), mixed foods
(AOR 5.0 [2.77, 9.02], p \ 0.001), and care at one of the
four hospitals (AOR 3.0 [1.51, 5.92], p = 0.002) were
more likely to be HIV-infected. While the administration
and uptake of WHO PMTCT guidelines is improving, an
expanded focus on retention and medication adherence will
further reduce pediatric HIV transmission.

& Sarah Finocchario-Kessler
skessler2@kumc.edu

Resumen Se analizaron los datos de prevención de la
transmisión materno-infantil (PTMI) de un cohorte retrospectivo de n = 1.365 VIH? madres que inscribieron a sus
bebés expuestos al VIH en los servicios de Diagnóstico
Temprano Infantil (Early Infant Diagnosis EID) en cuatro
hospitales del gobierno de Kenia del 2010-2012. Menos del
15% y el 20% de parejas madre-hijo fueron provistos de
regı́menes que cumplieron con las directrices de la OMS
(Organización Mundial de la Salud) opción A y B/B ?, respectivamente. Anualmente, la edad gestacional al momento
del inicio del tratamiento disminuyó, mientras que la absorción de la Opción B/B ? aumentó (todo de p \0,001). La
infección pediátrica del VIH se redujo a la mitad (8,6% a
4,3%), pero ha variado significativamente por hospital. En los
análisis multivariable, los bebés expuestos al VIH que no
recibieron la PTMI (AOR 4,6 [2,49, 8,62], p \0,001),
alimentos mixtos (AOR 5,0 [2,77, 9,02], p \0,001), y la
atención en uno de los cuatro hospitales (AOR 3,0 [1,51,
5,92], p = 0,002) tenı́an más probabilidades de estar infectados
por el VIH. Mientras que la administración y el seguimiento
de las normas de PTMI de la OMS están mejorando, un enfoque ampliado sobre la retención y adherencia a la medicación reducirá aún más la transmisión del VIH pediátrico.
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Despite a consorted effort to expand access to HIV testing
in antenatal care (ANC) and antiretroviral (ARV) prophylaxis for HIV? pregnant women [1, 2], Kenya continues to
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struggle to provide comprehensive HIV prevention and
treatment services for women and infants. In 2012, an estimated 86,000 (76,000–97,000) pregnant women in Kenya
were living with HIV [3]. Among HIV-positive mothers,
53 % [47–60 %] received ARV prophylaxis during pregnancy, however; an estimated one-third received an
inadequate or inferior ARV regimen [1–3]. Roughly 13,000
(10,000–17,000) [3] children ages 0–14 were newly infected in 2012. Furthermore, only 39 % [34–44 %] [4] of
HIV-exposed infants receive timely virologic testing by
6 weeks of age in accordance with World Health Organization (WHO) guidelines.
In 2010, the WHO revised global guidelines for the prevention of mother-to-child transmission of HIV (PMTCT)
outlining two options: A and B [5]. Option A was a shortterm prophylaxis of zidovudine during pregnancy and single
dose of nevirapine and zidovudine ? lamivudine at delivery
plus six additional daily doses of zidovudine ? lamivudine
for the mother and daily nevirapine syrup for infants
throughout breastfeeding. Option B was maternal triple-drug
ARV regimens throughout pregnancy and breastfeeding and
daily infant nevirapine or zidovudine until 4–6 weeks postpartum. Both options were recommended for HIV? pregnant women whose CD4 count or clinical staging did not
otherwise make them eligible for treatment (\350 cells/
mm3 or clinical stage 3 or 4). The target for antenatal ARV
initiation was also shifted from 28 to 14 weeks gestation [5].
In January 2010 the Kenya National AIDS & STI Control
Programme (NASCOP) scaled up their PMTCT services to
support WHO Option A [6].
In response to the overwhelming evidence of the
benefits of early treatment initiation [7, 8], negative impact on mothers’ health of stopping ARVs postpartum,
and global goals to eliminate new infections among
children [9], new updated PMTCT guidelines were introduced in 2012. These updated guidelines introduced
Option B? which calls for ART initiation for all pregnant
women upon HIV? diagnosis, regardless of CD4 count,
Fig. 1 Explanation of WHO
PMTCT Guidelines. Note
Adapted from [10, p. 2]

with sustained lifelong treatment [10]. These guidelines
also strongly promoted immediate initiation of Option
B/B? and clarified their superiority over Option A. In
response, in 2012, Kenya called for a transition to WHO
Option B? with the goal of national implementation by
2014 [4, 11]. See Fig. 1 for regimen and initiation period
for each guideline.
Despite concerted efforts to provide treatment that is
consistent with guidelines, clinical and patient-related
barriers continue to negatively impact implementation.
Clinical and system level barriers include inadequate and
inconsistent training of clinical staff that results in delayed
implementation of new guidelines [12–14], provision of
less efficacious ARV regimens [12], and weak systems to
support prospective patient follow up and retention [12,
14–16]. Many patients initiate treatment late and fail to
maximize ANC (only 50 % of Kenyan women complete
the four or more recommended antenatal appointments)
[17]. Furthermore, poor medication adherence during
pregnancy compromises the efficacy of medications [18,
19], and a multitude of factors (e.g., limited male partner
support, resource constraints, and HIV-stigma) all contribute to incomplete retention in PMTCT and EID services
[12, 14–16, 20]. Maintaining maternal support for treatment adherence is critical throughout the postpartum and
breastfeeding periods, as only half of HIV? mothers referred for ART after delivering their child actually followup on their own care [21].
To better understand recent trends and target future efforts in Kenya, this paper examined prescribing adherence
to the 2010 WHO PMTCT guidelines and progress made
toward 2012 Option B/B? recommendations at four government hospitals. We assessed the proportion of mothers
who received PMTCT, whether or not their treatment met
WHO guidelines in regard to gestational week of treatment
initiation and treatment regimen, and subsequent pediatric
HIV infection. Given Kenya’s goal to achieve consistent
nationwide WHO Option B? implementation by 2014 and

WHO 2010-2012 PMTCT Guidelines
Option A:
Antepartum: AZT starting as early as 14 weeks gestation.
Intrapartum: at onset of labor, sdNVP and first dose of AZT/3TC.
Postpartum: daily AZT/3TC through 7 days postpartum.

OR
Option B:
Triple ARVs starting as early as 14 weeks gestation and continued intrapartum and through
childbirth if not breastfeeding or until 1 week after cessation of all breastfeeding.

OR
Option B+ (2012 addendum):
Regardless of CD4 count, triple ARVs starting as soon as diagnosed, continued for life.
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reduce perinatal transmission to \5 % by 2015, these data
provide insight into current implementation practices and
areas to target for improvement.

Methods
We conducted a retrospective cohort analysis among 1365
HIV? mothers who enrolled their HIV-exposed infants in
early infant diagnosis (EID) services at four government
hospitals that were piloting the HIV infant tracking system
(HITSystem) intervention between April 2011 and December 2012. The HITSystem is an online intervention implemented at health facilities and central laboratories to
maximize efficiency of HIV DNA PCR testing, and improve
communication of results to mother/guardians, linkage to
HIV treatment, and retention in EID. A detailed description
of the HITSystem intervention and its impact have been
previously published [22]. De-identified data regarding
mothers’ antenatal PMTCT history, infant feeding method
and postnatal ARV prophylaxis, the timing of infant testing,
and infant HIV status were collected through the HITSystem.
Only hospitals implementing the HITSystem during the
specified review period were included. Mother-infant pairs
were located in both peri-urban hospitals in Western Kenya
(Hospitals A and B, both district level hospitals) and urban
Nairobi health facilities [Hospitals C (high volume facility in
a densely populated and underserved area) and D (referral
maternity hospital)] with EID volumes ranging from 8.5 to
21.2 HIV-exposed infants per month.

Procedures
As per the existing protocol at each of the hospitals, data regarding mothers’ PMTCT history were collected from mother’s medical file at the time of enrolling their infant in EID care.
Maternal and infant data were collected through the HITSystem
electronic database for the duration of the infant’s enrollment in
EID care. Mothers’ were informed about the HITSystem and
provided oral informed consent or declined participation
(\1 %, recorded in enrollment notebook), in which case their
information was collected in the EID Registry (standard of
care). Participation involved minimal risk, and a signed consent
form would have been the only document outside of protected
medical records that would have linked the participant to their
HIV? serostatus. All patient records/information was anonymized and de-identified prior to analysis. Detailed methods
regarding the implementation and data collection strategy for
the HITSystem have been previously published [22]. The study
protocol was approved by the Institutional Review Board at the
Kenya Medical Research Institute (KEMRI) and the University
of Kansas Medical Center.
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Measures
PMTCT Treatment Guidelines
To examine provider adherence to WHO guidelines, we
modified an established method for coding PMTCT
guideline adherence described by Azcoaga-Lorenzo and
colleagues [14]. Specifically, data for each mother-infant
pair was coded as: (1) no intervention (no ARV prescribed), (2) late treatment initiation (correct ARV regimen
combination prescribed later than WHO guidelines recommend), (3) initiation of WHO Option A, or (4) initiation
of WHO Option B/B?. All recorded ARV regimens met
the treatment criteria for either WHO Option A or WHO
Option B/B?. Reported rates of adherence to guidelines
reflect the proportion of providers that prescribed treatment
regimens in perfect agreement with WHO PMTCT guidelines. For this study, we have opted to use the ‘Option
B/B?’ categorization given the fact that WHO 2012
guidelines and the Kenya government endorse Option B?.
However, the examination of life-long provision of Option
B? was not possible as long-term maternal follow-up was
beyond the scope of the study.
Trends in PMTCT
In order to determine year that PMTCT was accessed,
mother-infant pairs were assigned to a calendar year of
treatment based on their infant’s date of birth and an assumed
40 week gestation period. Specifically, pairs were assigned
to the year in which the majority of the final 30 weeks of
gestation occurred (i.e., 1 = 2010, 2 = 2011, 3 = 2012).
To examine trends in PMTCT regimen administration,
we calculated the proportion receiving each regimen type
(i.e., late, WHO A or WHO B/B?) over the total number of
pairs who were prescribed any PMTCT. To examine trends
in the timing of treatment initiation, we determined the
gestational week when PMTCT was initiated for all pairs
that received any PMTCT. We then compared the average
gestational week of initiation across year of enrollment.
We calculated the proportion of infants who received
postnatal prophylaxis: (1) NVP for 6 weeks, (2) NVP for
6 months, or (3) other treatment, over the total number of
infants whose mother’s were prescribed PMTCT. Finally
we calculated the proportion of all HIV-exposed infants
who received cotrimoxazole in the context of EID services.
Pediatric HIV Transmission and Associated
Variables
Infant test results were coded as ‘0’ if HIV-negative, ‘1’ if
HIV-positive, and ‘2’ if the test result was indeterminate.

AIDS Behav (2016) 20:2602–2611

Positive HIV PCR results were calculated among all infants with a PCR test result. We compared the proportion
of HIV-positive results for each year of enrollment to examine trends in infant HIV transmission. Infant age at HIV
DNA PCR testing was calculated by comparing infant date
of birth to date of dried blood spot collection and analyzed
to report median age (in weeks). Other clinically relevant
variables that could affect transmission e.g., infant feeding
method at the time of testing (exclusive breast feeding,
replacement feeding, and mixed feeding), and postnatal
prophylaxis [ART (NVP for 6 weeks or 6 months) and
cotrimoxazole to prevent pneumocystis carinii pneumonia]
were collected from the HITSystem.
Hospital was included as a covariate to assess the impact
of the health facility where mother-infant pairs received
care. We assigned arbitrary titles (e.g. Hospital A, B etc.)
to each hospital rather than reporting them by name.

Analyses
Data from each hospital were cleaned and coded in separate excel files generated by the HITSystem before being
merged into SPSSÓ version 20 for analysis. Frequencies
and percentages were calculated for categorical variables
such as PMTCT treatment regimen and infant HIV infection, and measures of central tendency and variability
(mean, median, range, and standard deviation) were examined for continuous variables such as week of PMTCT
treatment initiation and infant age at first PCR test. An
ANOVA was used to determine if the week that mothers
initiated PMTCT treatment varied across the years examined. Significant omnibus results were followed-up with
Tukey HSD post hoc analyses to determine which years
were significantly different from others. We used v2 statistics to explore trends in the proportions of pairs receiving
Option B/B? and MTCT rates each year. Similarly, v2 tests
were used to determined significant differences in HIV
transmission by type of PMTCT regimen. We conducted
bivariate and multivariable logistic regression analyses to
assess associations between independent variables (PMTCT
regimen, hospital, infant feeding method, and postnatal
prophylaxis) and pediatric HIV transmission.

Results
PMTCT regimen was documented for 1134 (83.1 %)
mothers enrolled in EID at the study sites. Rates of mothers
who received some form of ARV therapy for PMTCT were
consistently higher in the urban versus peri-urban sites. The
majority of HIV? pregnant women (66.3 %) were prescribed a PMTCT regimen late (C14 gestational weeks).

2605

The most commonly prescribed regimens prior to 15 weeks
was ART in accordance with WHO Option B/B? guidelines (at Hospitals A, B, and D). AZT prescribed in accordance with WHO Option A was the most commonly
prescribed regimen at Hospital C. Infants’ first HIV PCR
test occurred at a median age of 6.8 (IQR 6.1) postnatal
weeks when the majority (84.4 %) were exclusively
breastfed. Administration of ART postnatal prophylaxis
was high across sites (92.8 %), with over half (54.8 %)
prescribed daily NVP for 6 months compared to the shorter
duration of 6 weeks (42.1 %). Table 1 displays a breakdown of the prescribed PMTCT regimen, postnatal prophylaxis, HIV testing, and feeding method by hospital.
Provider Adherence to PMTCT Guidelines
Overall, less than 20 % of mother-infant pairs were provided with services that met WHO 2010 Option B/B?
guidelines (i.e., ART commencing at 14 weeks gestation).
Hospital B experienced the highest rate of WHO 2010
Option B/B? guideline-consistent services, range 10 %
(Hospital D) to 42 % (Hospital B), see Table 1. Only 14 %
of mother-infant pairs were prescribed regimens that were
consistent with WHO 2010 Option A guidelines which
requires AZT commencing at 14 weeks gestation. An urban hospital (Hospital C) evidenced the highest rate of
adherence to WHO 2010 Option A guidelines (28 %) while
the other three sites experienced lower rates of adherence.
Trends in PMTCT Administration
Mean week of PMTCT treatment initiation among mothers
decreased from a high of 26.6 (SD 6.2) in 2010 to 19.9 (SD
11.34) in 2011 to 14.5 (SD 11.72) in 2012, as presented in
Fig. 2. A one-way ANOVA demonstrated a significant decrease in the mean week of treatment initiation over the
3 years [F(2, 1131) = 91.346, p \ 0.001], and post hoc
comparisons (Tukey HSD test) confirmed significant differences between each year, all p \ 0.001, (Table 2). Similarly,
the proportion of pairs receiving WHO Option B/B? was
calculated across hospitals for each year; resulting in \5 %
(CI 1.4–5.6 %) in 2010, 19.1 % (CI 16.2–22.0 %) in 2011 and
34.6 % (CI 29.6–39.6 %) by the end of 2012. Chi squared
tests confirmed significant differences in WHO Option B/B?
uptake between 2010 and 2011, v2(2) = 21.10, p \ 0.001,
2011 and 2012, v2(2) = 36.69, p \ 0.001, and 2010 and
2012, v2(2) = 79.25, p \ 0.001 (Fig. 2).
Pediatric HIV Transmission
The average pediatric HIV transmission rate over the
study period was 5.9 % (CI 4.6–7.2 %), ranging from a
low of 2.5 (CI 1.2–3.8 %, Hospital D) to a high of
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Table 1 Description of sample by hospital
Hospital
Mother-infant pairs

A

B

C

D

Total

203

324

287

551

1365

(14.9 %)

(23.7 %)

(21.0 %)

(40.4 %)

(100 %)

PMTCT regimen
Total of mothers on any PMTCT
Late PMTCT Initiation
WHO Option A
WHO Option B/B?

128/203

214/324

263/287

529/551

1134/1365

(63.1 %)

(66.0 %)

(91.6 %)

(96.0 %)

(83.1 %)

69/128

78/214

144/263

461/529

752/1134

(53.9 %)

(36.4 %)

(54.8 %)

(87.1 %)

(66.3 %)

27/128

46/214

73/263

14/529

160/1134

(21.1 %)

(21.5 %)

(27.8 %)

(2.6 %)

(14.1 %)

32/128

90/214

46/263

54/529

222/1134

(25.0 %)

(42.1 %)

(17.5 %)

(10.2 %)

(19.6 %)

176/203

275/324

271/287

545/551

1267/1365

(86.7 %)

(84.9 %)

(94.4 %)

(98.9 %)

(92.8 %)

Infant postpartum prophylaxis
Received ART prophylaxis
NVP for 6 weeks (only)

77/176

43/275

176/271

237/545

533/1267

(43.8 %)

(15.6 %)

(64.9 %)

(43.5 %)

(42.1 %)

98/176

230/275

92/271

274/545

694/1267

(55.7 %)

(83.6 %)

(33.9 %)

(50.3 %)

(54.8 %)

1/176

2/275

3/271

34/545

40/1267

(0.6 %)

(0.7 %)

(1.1 %)

(6.2 %)

(3.2 %)

203/203

319/324

286/287

551/551

1359/1365

(100.0 %)

(98.5 %)

(99.7 %)

(100.0 %)

(99.6 %)

203/203

313/324

283/287

548/551

1347/1365

(100.0 %)

(96.6 %)

(98.6 %)

(99.5 %)

(98.7 %)

Median infant age (in weeks) at first PCR

6.64

9.00

6.57

6.57

6.86

Infants testing HIV?

SD 17.71
19/203

SD 15.74
18/313

SD 12.57
28/283

SD 13.04
14/548

SD 14.41
79/1347

(9.3 %)

(5.7 %)

(9.9 %)

(2.5 %)

(5.9 %)

1/203

4/313

1/283

0/548

6/1347

(0.5 %)

(1.3 %)

(0.3 %)

(0 %)

(0.4 %)

168/195

238/299

252/285

464/551

1122/1330

(86.2 %)

(79.6 %)

(88.4 %)

(84.2 %)

(84.4 %)

10/195

19/299

4/285

61/551

94/1330

(5.1 %)

(6.4 %)

(1.4 %)

(11.1 %)

(7.1 %)

17/195

42/299

29/285

26/551

114/1330

(8.7 %)

(14.0 %)

(10.2 %)

(4.7 %)

(8.6 %)

NVP for 6 months
Other regimena
Received cotrimoxazole
Infant HIV testing
Infants tested for HIV

Infants with an indeterminate
HIV test result
Infant feeding method
Breastfeeding Only
Replacement feeding only
Mixed feeding
a

Infant postpartum regimens were combined into the ‘‘other’’ category based on their small percentages. These regimens include ‘‘AZT for
6 weeks’’ N = 5; ‘‘single-dose nevirapine’’ N = 3, and ‘‘AZT ? 3TC QID 9 1 week’’ N = 32. Infant feeding method was not available for all
pairs

9.9 % (CI 6.4–13.4 %, Hospital C); both located in
Nairobi (Table 1). Pediatric HIV transmission rates
across hospitals decreased each year; 2010 8.6 % (CI
5.4–11.7 %), 2011 5.5 % (CI 3.8–7.2 %) and 2012 4.3 %
(CI 2.4–6.8 %) (Fig. 3). MTCT was significantly lower
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among women receiving PMTCT in 2012 compared to
women receiving PMTCT in 2010 (8.6 vs. 4.3 %;
v2(2) = 5.02, p = 0.025). Rates of indeterminate HIV
test results were consistently low across all sites with an
average of 0.4 %, range 0–1.3 %.
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Mean Week of Treatment Initiation

10.0%

40

9.0%

HIV-Indeterminate

8.0%

34.6%

7.0%

26.63

Percent

30

HIV-Posive

8.6%
(2.7-26.3%)

19.86

20

19.1%

14.49

5.5%

6.0%

(3.3-8.9%)

4.3%

5.0%

(0-8.3%)

4.0%
3.0%

10

2.0%
3.5%

0

1.0%

1.0%

2010

2011

2012

0.4%

0.0%

Fig. 2 Trends in PMTCT Guideline implementation in Kenya: Mean
week of PMTCT treatment initiation by year and uptake (%) of WHO
Option B/B? (2010–2012). Changes between each year: 2010–2011,
2011–2012, and 2010–2012 are statistically significant (p \ 0.001)
for annual increases in Option B/B? initiation and annual decreases
in mean gestational week at treatment initiation

Predictors of Pediatric HIV Transmission
Table 3 documents variation in HIV transmission rates according to PMTCT regimen prescribed to mother-infant
pairs. Women who were prescribed any PMTCT regimen
(n = 1123) were significantly less likely to transmit HIV
compared to those not prescribed PMTCT (n = 214; 3.6 %
[CI 2.6–4.8 %] vs. 18.2 % [CI 13.6–23.9 %], v2(1) = 51.62,
p \ 0.001). However, HIV transmission rates did not vary
significantly by PMTCT regimen (i.e., late initiation 3.1 %;
CI 2.1–4.6 %, WHO Option A 4.5 %; CI 2.2–9.0 %, or
Option B/B? 4.6 %; CI 2.5–8.2 %, v2(2) = 1.52,
p = 0.467).
Any PMTCT (vs. none), mixed feeding method, and hospital where care was received were significantly associated
with pediatric transmission in bivariate analyses (p \ 0.05).
In multivariable analyses (Table 4), HIV-exposed infants
who did not receive PMTCT and those who received mixed

2010
N = 304

2011
N = 693

0.0%

2012
N = 346

Year

Fig. 3 HIV? DNA PCR test results among HIV-exposed infants
enrolled in EID by year, % (range between hospitals), 2010–2012

feeding were significantly more likely to be HIV? (AOR 4.6
[2.49, 8.62], p \ 0.001, and AOR 5.0 [2.77, 9.02],
p \ 0.001), respectively. HIV-exposed infants seeking care
from a high volume yet low resource health facility
(Hospital C) were three times more likely to test HIV?
compared to HIV-exposed infants receiving care at the
other facilities (AOR 3.0 [1.51, 5.92], p = 0.002).

Discussion
These findings illustrate a promising trend towards the
earlier administration of more efficacious ARV PMTCT
regimens; with statistically significant improvements
achieved each year between 2010 and 2012. Coverage of
PMTCT was high at 83 % (range 63–96 %), yet still shy of
the 90 % target set by WHO [23]. Late PMTCT implementation (average of 28 weeks) was high when averaged
across sites (66.3 %), while uptake of the 2010 WHO

Table 2 Post-hoc analyses for changes in mean week of treatment initiation by year
Gestational year

N

Mean

Standard
deviation

Standard
error

95 % CI
Lower bound

Upper
bound

2010

257

26.63

6.22

0.388

25.87

27.39

2011

585

19.86

11.34

0.469

18.94

20.78

2012

292

14.49

11.72

0.686

13.14

15.84

Total

1134

20.01

11.32

0.336

19.35

20.67

SS
Between groups

df

20,186.841

2

Within groups

124,972.052

1131

Total

145,158.893

1133

F

p

91.346

0.000
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Table 3 Likelihood of HIV transmission compared by PMTCT intervention: Infants with positive HIV DNA PCR test results among the 1337
HIV-exposed infants with conclusive PCR test results at four hospitals
A
(n = 202)

B
(n = 307)

C
(n = 281)

D
(n = 547)

Total
(n = 1337)

v2

p value

No PMTCT (n = 214)

18

13

7

1

39

v2(1) = 51.62

p \ 0.001

Mother on any PMTCT regimen (n = 1123)

(24.3 %)
1

(13.5 %)
5

(30.4 %)
21

(4.8 %)
13

(18.2 %)
40

(0.8 %)

(2.4 %)

(8.1 %)

(2.5 %)

(3.6 %)

Late AZT initiation: AZT starting at 15 weeks
gestation or later (n = 749)

1/69

1/78

9/142

12/460

23/749

v2(2) = 1.52

p = 0.467

(1.4 %)

(1.3 %)

(6.3 %)

(2.6 %)

(3.1 %)

Early AZT initiation: AZT starting 0–14 weeks
gestation (WHO Option A) (n = 155)

0/27

0/46

7/70

0/12

7/155

(0 %)

(0 %)

(10.0 %)

(0 %)

(4.5 %)

WHO Option B/B? (n = 219)

0/32

4/87

5/46

1/54

10/219

(0 %)

(4.6 %)

(10.9 %)

(1.6 %)

(4.6 %)

Mother received PMTCT

ART regimen

Denominators in the ART regimen section of this table represent the total number of mothers to receive the aforementioned PMTCT regimen at
that particular hospital
The sum of all the denominators plus the number of mothers that did not receive PMTCT (n = 214) equals 1337
Total of 1337 includes all confirmed PCR results, thus excludes indeterminate (n = 6) or missing (n = 4) results
Numerators are the number of positive infants by regimen and hospital. The sum of the numerators in the ART regimen section will equal the
number of mothers on any PMTCT regimen

Table 4 Bivariate and
multivariable logistic regression
analyses to identify predictors
of pediatric HIV transmission
among mother-infant pairs
enrolled in EID

No PMTCT

Bivariate
OR [95 % CI], p

Multivariable
AOR [95 % CI], p

6.0 [3.78, 9.65], p \ 0.001

4.6 [2.49, 8.62], p < 0.001

PMTCT regimen
Late initiation

0.662 [0.310, 1.41], p = .286

WHO Option A

0.989 [0.368, 2.66], p = .982

WHO Option B (reference)
Hospital
3.9 [1.92, 7.95], p \ 0.001

1.55 [0.672, 3.57], p = .304

Hospital B

2.3 [1.15, 4.78], p = 0.019

0.67 [0.279, 1.61], p = .369

Hospital C
Hospital D (reference)

4.1 [2.11, 7.86], p \ 0.001

3.0 [1.51, 5.92], p = 0.002

Replacement feeding

0.254 [0.035, 1.86], p = 0.178

0.303 [0.040, 2.26], p = 0.244

Mixed feeding

7.43 [4.36, 12.63], p \ 0.001

5.0 [2.78, 9.02], p < 0.001

Hospital A

Infant feeding

Breastfeeding (reference)
Bold values are statistically significant (p \ 0.05)

Option A and Option B/B? regimens (by 14 weeks) was
low; 14.1 and 19.6 % respectively. While Kenya is
definitely moving in the right direction, challenges to the
full implementation of the 2010 and more aggressive 2012
WHO PMTCT guidelines persist.
Despite less than optimal adoption of the latest WHO
PMTCT guidelines, pediatric HIV transmission decreased
significantly each year between 2010 and 2012 at these
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four government hospitals. The transmission across study
hospitals in 2012 was 4.3 % (0–8.3 %), which meets the
national and global target of \5 % MTCT. In fact, this rate
is comparable to that (4.1 %) achieved by a formal programmatic intervention that provided adherence and retention support throughout the PMTCT cascade conducted
in Malawi [25]. This 4.3 % average observed across study
hospitals is significantly lower than the 2013 national

AIDS Behav (2016) 20:2602–2611

Kenyan average of 14.3 % MTCT [24], which includes a
more representative denominator of all HIV-exposed infants; rather than only those engaged in care. This clinicbased sample of mother-infant pairs engaged in EID likely
under represents the highest-risk mothers and infants most
vulnerable to transmission.
In contrast to our expectations and the existing literature
evaluating PMTCT treatment regimens, [26–28] the earlier
administration of more rigorous PMTCT regimens was not
significantly associated with decreased infant HIV transmission when analyzed at the individual level. It’s possible
that these data on initial regimen and timing of initiation,
which were recorded by healthcare providers in clinical
records, were not a perfect reflection of what mothers really ended up taking during their pregnancies. While the
significant association between hospital and infant transmission rates cannot be explained by data collected in this
study, we hypothesize that findings may be attributable to
site-specific conditions like the varying PMTCT staff
training, quality of patient records and PMTCT registry
data, frequency of test kit and medication stock outs, and
HIV prevalence among communities utilizing respective
hospitals. The referral maternity hospital that draws patients from a much wider catchment area observed the
lowest transmission (2.5 %), while a high volume health
center located in an urban slum observed the highest
transmission (9.9 %); both in the same city. Our findings
emphasize the importance of facility-related variables to
maximizing the benefit of PMTCT interventions.
The gap between initial administration of a PMTCT
regimen and the daily events that occur before, during, and
after delivery are significant. These data highlight the importance of measuring outcomes across the complete
PMTCT cascade [29] including appointment attendance,
medication adherence (pharmacy refill records, self-report
adherence and viral load), viral resistance to current ART
regimens, and retention throughout pregnancy and the
postnatal period. Data from neighboring Tanzania finds that
\10 % of mothers maintained at least 80 % adherence to
medications during the pre, intra- and postpartum periods
[19]. In Kenya, nearly one-third of pregnant women on
ART in facilities in western Kenya leave care prior to
delivery [30]. Consequently, progress made by initiating
rigorous regimens early in the gestational period may become squandered without adequate support systems for
adherence and retention; posing more complicated and
long term challenges.
These data demonstrate the pace of policy implementation after the 2010 WHO PMTCT guidelines at four
hospitals in Kenya and are linked to EID outcomes; the
ultimate evaluation of PMTCT effectiveness. While these
data provide timely and valuable insights regarding progress made toward national and global targets for
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eliminating MTCT, they should be interpreted in light of
several limitations. Data in this sample are limited to HIVinfected mothers who presented with their infants for EID,
which is estimated at 66 % of all HIV-exposed infants in a
recent meta-analysis among 11 sub-Saharan countries [31].
Consequently, this study may reflect PMTCT data from
healthier and more empowered women with live births.
Data were gathered from medical chart review for those
who received ANC at the same hospital they were seeking
EID, however; for the few mothers without an existing
antenatal record (\5 %), self-reported maternal history was
used. Data were limited by the completeness and accuracy
of clinical records and PMTCT registries which may under
or over- estimate the proportion of women who received
some degree of PMTCT. Importantly, these data reflect
provider administration of a PMTCT regimen rather than
patients’ actual medication adherence or retention in services. Consequently, it cannot be determined if PMTCT
medications were taken consistently, correctly, or at all.
Furthermore, at the time of this study, demographic variables such as education level and socioeconomic status
were not routinely recorded in the HITSystem; limiting
analyses for predictors of PMTCT uptake or perinatal HIV
transmission. These data only include gestational period
through the end of 2012 and thus do not capture improvements made in 2013 or beyond.

Conclusions
Kenya continues to improve PMTCT services by administering more efficacious ARV regimens earlier in the antenatal period. These improvements are verified by annual
declines in pediatric HIV transmission between 2010 and
2012. Significant differences in infant HIV transmission
among hospitals and the lack of association between rigor
of PMTCT regimen and pediatric HIV transmission data,
illuminate that proper administration of PMTCT regimens
is only one of several critical steps in reducing vertical
transmission. Measuring medication adherence and retention throughout the PMTCT cascade of care are essential to
understanding the real impact of PMTCT efforts.
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